Tuesday, October 21, 2014 12:11:10 PM
you have 3 moderators here, at least one is a promoter (or is maybe internal IR themselves) who should be able to give you some type of answer, and if they're not IR, they are at least under the direction of the company
HOGWASH... I am a shareholder... I do my own DD and pick stocks I choose to speculate in... occasionally I like one well enough to take on being a mod and giving some extra time to the stock board!
I am NOT under the direction of anyone at ONVO... and FYI anyone who IS under the direction of the company could only give you non-material information or REPEAT material information that has already been made known in public filings by the company.
Sometimes partners or those collaborating on R&D projects talk out of school and let information slip... rare but it happens.
That there are over 100 funds invested in ONVO holding 20+% of the shares is a very good thing. Also it is good that the liver assays have a 40+ day viability. Commercial revenue coming in soon will change the game somewhat...
The PPS is being played and manipulated by some because there are not that many who are aware of ONVO yet. ONVO was an OTC stock not too long ago... the OTC is a manipulated BOGUS market that many small companies just languish and die due to the attacks on them by greedy entities as the regulators look the other way.
The new step up in trading market has only changed that manipulation game slightly... it will take revenue, known partners, and continued progress to get enough exposure for ONVO to gain a shareholder following and base sufficient to SNUFF OUT the manipulators and their games!
"I call investing the greatest business in the world because you never have to swing... All day you wait for the pitch you like,... The problem when you're a money manager is that your fans keep yelling, 'Swing. you bum!'"
W. Buffett
Recent VIVS News
- VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing • GlobeNewswire Inc. • 04/28/2026 12:05:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/06/2026 05:27:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:05:10 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 04/02/2026 08:00:55 PM
- VivoSim Announces Pricing of up to a $4 Million Public Offering • GlobeNewswire Inc. • 04/01/2026 12:05:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/31/2026 02:17:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 09:26:52 PM
- VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs • GlobeNewswire Inc. • 03/24/2026 12:05:00 PM
- VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales • GlobeNewswire Inc. • 03/03/2026 01:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:05:26 PM
- VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego • GlobeNewswire Inc. • 02/11/2026 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:59:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2026 12:51:43 AM
- VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China • GlobeNewswire Inc. • 01/29/2026 09:05:00 PM
- VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer • GlobeNewswire Inc. • 01/06/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2025 09:05:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2025 11:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 09:08:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/03/2025 09:07:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/03/2025 09:06:32 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/28/2025 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2025 12:45:18 AM
